





Andreas JURIK

How would you summarize your thesis results in 3 sentences?

Making use of the individual toolboxes of institutions participating in MolTag, it was possible to elaborate and experimentally challenge hypotheses based on in-silico calculations. This helped gaining insights to the molecular determinants of ligand recognition and transporter subtype differentiation in the GABA reuptake system.

What are you doing now?

Managing marketing authorization applications and lifecycle strategies for medicinal products with a focus on cardiology and intensive care on European and global level.

What was the impact of the MolTag program on your further career?

The MolTag program helped **me to broaden the picture on possible strategies to approach complex questions**. Deeper understanding of – back then – current trends in science and big pharma is also now facilitating **to bridge the worlds of cutting-edge pharmaceutical development to established frameworks in regulatory authorities**.

Did you keep connection with some former colleagues?

I am happy that the contact with some former colleagues is still active, and I hope it will stay like this.

What is your recommendation for current MolTag students?

Challenge yourself, your goals and your project on a regular basis.





**Supervisor:** Gerhard Ecker, Faculty of Life Sciences, Univ.

of Vienna

Thesis title: In Silico
Evaluation of Inhibitor Binding
Modes in the GammaAminobutyric Acid
Transporter System.

Current Position and Employer: Senior Regulatory Affairs Manager\_at AOP Orphan Pharmaceuticals AG, Vienna, Austria

MolTag alumni page:
Andreas Jurik (univie.ac.at)

Social network:

Andreas Jurik | LinkedIn





